ИММУНОПАТОГЕНЕЗ И ПЕРСПЕКТИВЫ ИММУНОМОДУЛИРУЮЩЕЙ ТЕРАПИИ ВИЧ-ИНФЕКЦИИ Часть 2. МЕДИЦИНСКИЕ ВОПРОСЫ
https://doi.org/10.22328/2077-9828-2017-9-3-7-15
Аннотация
Об авторе
А. С. Симбирцев
ФГУП «Государственный научно-исследовательский институт особо чистых биопрепаратов» ФМБА России
Россия
член-корреспондент РАН, зам. директора по научной работе ФГУП «Государственный научно-исследовательский институт особо чистых биопрепаратов» ФМБА России, +7 812 235-12-25, 197110, Санкт-Петербург, Пудожская ул., 7
Россия
член-корреспондент РАН, зам. директора по научной работе ФГУП «Государственный научно-исследовательский институт особо чистых биопрепаратов» ФМБА России, +7 812 235-12-25, 197110, Санкт-Петербург, Пудожская ул., 7
Список литературы
1. Maartens G., Celum C., Lewin S. HIV infection: epidemiology, pathogenesis, treatment and prevention. Lancet, 2014, Vol. 384, рр. 258–271.
2. Migueles S., Connors M. Success and failure of the cellular immune response against HIV 1. Nat. Immunol., 2015, Vol. 16, pp. 563–570.
3. Jain V., Hartogensis W., Bacchetti P., Hunt P.W., Hatano H., Sinclair E., Epling L., Lee T.H. Antiretroviral Therapy Initiated Within 6 Months of HIV Infection Is Associated With Lower T-Cell Activation and Smaller HIV Reservoir Size. J. Infect. Dis., 2013, Vol. 208, pp. 1202–1211.
4. Hunt P., Sinclair E., Rodriguez B., Shive C., Clagett B., Funderburg N., Robinson J., Huang Y., Epling L. Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection. J. Infect. Dis., 2014, Vol. 210, pp. 1228–1238.
5. Селимова Л.М., Калнина Л.Б., Серебровская Л.В., Иванова Л.А., Гуляева А.Н., Носик Д.Н. Цитокины при инфекции, вызванной вирусом иммунодефицита человека 1-го типа (ВИЧ-1) // Вопросы вирусологии. 2016. Т. 61, № 1. С. 39–41.[Selimova L.M., Kalnina L.B., Serebrovskaya L.V., Ivanova L.A., Gulyaeva A.N., Nosik D.N. Cytokines in infections caused by human immunodeficiency virus 1 type (HIV-1). Problems of Virology, 2016, Vol. 61, No. 1, pp. 39–41(In Russ.)].
6. Smith C., Ryom L., Weber R., Morlat P., Pradier C., Reiss P., Kowalska J.D., de Wit S., Law M., el Sadr W., Kirk O., Friis-Moller N., Monforte A.D., Phillips A.N., Sabin C.A., Lundgren J.D. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet, 2014, Vol. 384, pp. 241–248.
7. Lucas S. Causes of death in the HAART era. Curr. Opin. Infect. Dis., 2012, Vol. 25, pp. 36–41.
8. Tenorio A., Zheng Y., Bosch R., Krishnan S., Rodriguez B., Hunt P.W., Plants J. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J. Infect. Dis., 2014, Vol. 210, pp. 1248–1259.
9. Lundgren J., Babiker A., Gordin F., Emery S., Grund B., Nordwall J., Quan K., Quan S.F., Schultz T., Sharma S., Thompson G., Lundgren J.D. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N. Engl. J. Med., 2015, Vol. 373, pp. 795–807.
10. French M., Lenzo N., John N., Mallal S.A., McKinnon E.J., James I.R., Price P. Immune restoration disease after the treatment of immunodefi- cient HIV-infected patients with highly active antiretroviral therapy. HIV Med., 2005, Vol. 1, pp. 107–115.
11. Hsu D., Sereti I. Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection. Drugs, 2016, Vol. 76, pp. 533–549.
12. Bandera A., Colella E., Rizzardini G., Gori A., Clerici M. Strategies to limit Immune-activation in HIV patients. Expert Rev. Anti-Infect. Ther., 2016, Vol. 4, pp. 1–12.
13. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med., 2009, Vol. 361, pp. 2209–2220.
14. Haynes B., Gilbert P., McElrath M., Zolla-Pazner S., Tomaras G.D., Munir Alam S., Evans D.T., Montefiori D.C., Chitraporn Karnasuta, Sutthent R., Liao H.X., DeVico A.L., Lewis G.K., Williams Constance, Pinter A., Fong Y., Janes H., DeCamp A., Huang Y., Rao M., Billings E., Karasavvas N. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med., 2012, Vol. 366, pp. 1275–1286.
15. Gray G., Laher F., Lazarus E., Ensoli B., Corey L. Approaches to preventative and therapeutic HIV vaccines. Curr. Opin. Virol., 2016, Vol. 17, pp. 104–109.
16. Ho D., Hartshorn K., Rota T., Andrews C.A., Kaplan J.C., Schooley R.T., Hirsch M.S. Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet, 1985, Vol. 1 (8429), pp. 602–604.
17. Rivero J., Fraga M., Cancio I., Cuervo J., Lopez-Saura I.P., Sanatorio I. Long-term treatment with recombinant interferon alpha-2b prolongs survival of asymptomatic HIV-infected individuals. Biotherapy, 1997, Vol. 10, pp. 107–113.
18. Lane H., Kovacs J., Feinberg J. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi’s sarcoma. Lancet, 1988, Vol. 2 (8622), pp. 1218–1222.
19. Asmuth D., Utay N., Pollard R. Peginterferon α-2a for the treatment of HIV infection. Expert Opin. Investig. Drugs, 2016, Vol. 25, pp. 249–257.
20. Abrams D., Levy Y., Losso M., Babiker A., Collins G., Cooper D.A., Darbyshire J. Interleukin-2 therapy in patients with HIV infection. New Engl. J. Med., 2009, Vol. 361, pp. 1548–1559.
21. Markowitz N., Lopardo G., Wentworth D., Gey D., Babiker A., Fox L. Long-Term Effects of Intermittent IL-2 in HIV Infection: Extended Follow-Up of the INSIGHT STALWART Study. PLoS One, 2012, Vol. 7, pp. e47506.
22. Chahroudi A., Silvestri G. Interleukin-7 in HIV pathogenesis and therapy. Eur. Cytokine Netw., 2010, Vol. 21, pp. 202–207.
23. Levy Y., Lacabaratz C., Weiss L., Viard J.P., Goujard C., Lelievre J.D. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J. Clin. Invest., 2009, Vol. 119, pp. 997–1007.
24. Coiras M., Bermejo M., Descours B., Mateos E., García-Pérez J., Alcamí J. IL-7 Induces SAMHD1 Phosphorylation in CD4+ T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle. J. Cell. Rep., 2016, Vol. 14, pp. 2100–2107.
25. Crawley A., Angel J. The influence of HIV on CD127 expression and its potential implications for IL-7 therapy. Semin. Immunol., 2012, Vol. 24, pp. 231–240.
26. Nguyen T.P., Shukla S., Asaad R., Freeman M.L., Lederman M.M., Harding C.V., Sieg S.F. Responsiveness to IL-7but not to IFN- is diminished in CD4+ T cells from treated HIV infected patients who experience poor CD4+ T-cell recovery. AIDS, 2016, Aug. 24, Vol. 30 (13), pp. 2033–2042.
27. Katlama C., Lambert-Niclot S., Assoumou L., Papagno L., Lecardonnel F., Zoorob R. Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial. AIDS, 2016, Vol. 30, pp. 221–230.
28. Napolitano L., Schmidt D., Gotway M., Ameli N., Filbert E.L., Ng M.M. Growth hormone enhances thymic function in HIV-1-infected adults. J. Clin. Invest., 2008, Vol. 118, pp. 1085–1098.
29. Lindboe J., Langkilde A., Eugen-Olsen J., Hansen B.R., Haupt T.H. Low-dose growth hormone therapy reduces inflammation in HIV-infected patients: a randomized placebo-controlled study. Infect. Dis., 2016, Vol. 48, pp. 829–837.
30. Herasimtschuk A., Downey J., Nelson M., Moyle G., Mandalia S., Sikut R., Gotch F., Imami N. Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection. Vaccine, 2014, Vol. 32, pp. 7005–7013.
31. Van Der Ryst E. Maraviroc — A CCR5 Antagonist for the Treatment of HIV-1 Infection. Front. Immunol., 2015, Vol. 6, pp. 277–284.
32. Serrano-Villar S., Sainz T., Ma Z., Utay N.S., Wook-Chun T., Mann S. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial. PLoS Pathog., 2016, Vol. 12, pp. e1005381.
Рецензия
Для цитирования:
Симбирцев А.С. ИММУНОПАТОГЕНЕЗ И ПЕРСПЕКТИВЫ ИММУНОМОДУЛИРУЮЩЕЙ ТЕРАПИИ ВИЧ-ИНФЕКЦИИ Часть 2. МЕДИЦИНСКИЕ ВОПРОСЫ. ВИЧ-инфекция и иммуносупрессии. 2017;9(3):7-15. https://doi.org/10.22328/2077-9828-2017-9-3-7-15
For citation:
Simbirtsev A.S. IMMUNOPATHOGENESIS OF AND PROSPECTS FOR IMMUNOMODULATORY THERAPY FOR HIV INFECTION Part 2. MEDICAL ISSUES. HIV Infection and Immunosuppressive Disorders. 2017;9(3):7-15. (In Russ.) https://doi.org/10.22328/2077-9828-2017-9-3-7-15
Просмотров: 711
.png)
Послать статью по эл. почте 